These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3500691)

  • 1. Natural killer activity of lymphocytes infiltrating human lung cancers following preoperative systemic recombinant interleukin 2.
    Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun S; Holmes C; Golub SH
    Arch Surg; 1987 Dec; 122(12):1446-50. PubMed ID: 3500691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
    Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH
    Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood and tumor infiltrating lymphocytes in non-small cell lung cancer: analysis at the population and clonal level.
    Viale M; Ferrini S; Serrano S; Serrano D; Ardizzoni A; Nicolin A
    Tumori; 1990 Oct; 76(5):488-94. PubMed ID: 2175060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
    Lanier LL; Benike CJ; Phillips JH; Engleman EG
    J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients.
    Nakamura H; Ishiguro K; Mori T
    Cancer; 1988 Dec; 62(12):2489-97. PubMed ID: 3142676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of natural killer activity of lymphocytes infiltrating human lung cancers.
    Anderson TM; Ibayashi Y; Holmes EC; Golub SH
    Cancer Immunol Immunother; 1987; 25(1):65-8. PubMed ID: 3109739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antitumor activity of human tumor infiltrating lymphocytes (TIL) and its comparison with peripheral blood lymphocytes (PBL)].
    Xu ZY
    Zhonghua Zhong Liu Za Zhi; 1990 Sep; 12(5):345-7. PubMed ID: 2177396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
    Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
    J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological and functional characteristics of tumor-infiltrating lymphocytes from human colorectal cancers after stimulation with rIL-2.
    Keller H; Wimmenauer S; Rahner S; Reimer P; von Kleist S; Farthmann EH
    Eur Surg Res; 1995; 27(4):258-68. PubMed ID: 7649213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.
    Itoh K; Tilden AB; Kumagai K; Balch CM
    J Immunol; 1985 Feb; 134(2):802-7. PubMed ID: 3917475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.
    Phillips JH; Gemlo BT; Myers WW; Rayner AA; Lanier LL
    J Clin Oncol; 1987 Dec; 5(12):1933-41. PubMed ID: 3500280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
    Itoh K; Platsoucas CD; Balch CM
    J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer.
    Pisani RJ; Krco CJ; Wold LE; McKean DJ
    Am J Clin Pathol; 1989 Oct; 92(4):435-46. PubMed ID: 2552792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
    Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
    J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
    Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
    Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
    Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
    Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes.
    Massaro AF; Schoof DD; Rubinstein A; Zuber M; Leonard-Vidal FJ; Eberlein TJ
    Cancer Res; 1990 May; 50(9):2587-92. PubMed ID: 2139356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
    Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
    J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properties of recombinant interleukin 2-cultured tumor-infiltrating lymphocytes in human lung cancer.
    Yano T; Yasumoto K; Togami M; Ishida T; Kimura G; Sugimachi K; Nomoto K
    Int J Cancer; 1989 Apr; 43(4):619-23. PubMed ID: 2495250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.